Home > Insider Trading > Filing (0001209191-11-015190)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1100962	Endo Pharmaceuticals Holdings Inc	ENDP	Pharmaceutical Preparations (2834)	134022871

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1455549	J Edward Sweeney	C/O Endo Pharmaceuticals Holdings Inc. 100 Endo Boulevard Chadds Ford PA 19317	Principal Accounting Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $.01 Per Share	Acquisiton	2011-02-28	1,110	$0.00	1,110	No	4	M	Direct
Common Stock, Par Value $.01 Per Share	Disposition	2011-03-01	1,110	$35.11	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	2007 Stock Incentive Plan Restricted Stock Units(RSUs)	Disposition	2011-02-28	1,110	$0.00	1,110	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,219	2011-02-28	2011-02-28	No	4	M	Direct

Footnotes

This represents the vesting of restricted stock units granted to Mr. Sweeney in consideration of his services as the Principal Accounting Officer of Endo Pharmaceuticals Holdings Inc. Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc.
Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc.
Twenty-five percent (25%) of Mr. Sweeney's February 26, 2009 grant of restricted stock units (RSUs) generally vest 25% on each of February 26, 2010, February 26, 2011, February 26, 2012 and February 26, 2013. The 1,110 shown here is the amount that vested on February 26, 2011. Upon vesting, we consider the underlying RSUs to be expired.
These securities were granted to Mr. Sweeney in consideration of his services as the Principal Accounting Officer of Endo Pharmaceuticals Holdings Inc.